Financial reports
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
13 Aug 21
10-Q
2021 Q1
Quarterly report
14 May 21
10-K
2020 FY
Annual report
31 Mar 21
10-Q
2020 Q3
Quarterly report
19 Nov 20
Current reports
8-K
ProPhase Labs Announces Record Financial Results
28 Mar 23
8-K
ProPhase Labs Announces New $6 Million Stock Repurchase Program
15 Mar 23
8-K
Company in Early Stages of Exploring Development for Commercialization in Other Countries
1 Mar 23
8-K
Goal to launch commercially in Q4 2023
22 Feb 23
8-K
ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
15 Feb 23
8-K
ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
6 Feb 23
8-K
Entry into a Material Definitive Agreement
30 Jan 23
8-K
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
5 Jan 23
8-K
Departure of Directors or Certain Officers
28 Dec 22
8-K
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
20 Dec 22
Registration and prospectus
S-8
Registration of securities for employees
14 Nov 22
S-8
Registration of securities for employees
27 May 22
424B5
Prospectus supplement for primary offering
29 Dec 21
S-8
Registration of securities for employees
1 Dec 21
POS AM
Prospectus update (post-effective amendment)
18 Nov 21
S-3
Shelf registration
5 Nov 21
S-8
Registration of securities for employees
23 Aug 21
S-3
Shelf registration
21 Jun 21
S-8
Registration of securities for employees
3 Jun 21
424B5
Prospectus supplement for primary offering
20 Jan 21
Proxies
DEF 14A
Definitive proxy
13 Apr 22
DEF 14A
Definitive proxy
16 Apr 21
DEF 14A
Definitive proxy
16 Apr 20
DEF 14A
Definitive proxy
19 Apr 19
DEF 14A
Definitive proxy
19 Apr 18
DEF 14A
Definitive proxy
23 Mar 18
PRE 14A
Preliminary proxy
28 Feb 18
DEF 14A
Definitive proxy
20 Apr 17
DEF 14A
Definitive proxy
3 Mar 17
PRER14A
Preliminary revised proxy
24 Feb 17
Other
EFFECT
Notice of effectiveness
26 Nov 21
EFFECT
Notice of effectiveness
12 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
UPLOAD
Letter from SEC
9 Nov 21
EFFECT
Notice of effectiveness
30 Jun 21
CORRESP
Correspondence with SEC
25 Jun 21
UPLOAD
Letter from SEC
24 Jun 21
UPLOAD
Letter from SEC
22 Jun 21
CORRESP
Correspondence with SEC
11 Jun 21
UPLOAD
Letter from SEC
26 May 21
Ownership
4
Ted William Karkus
2 Feb 23
SC 13D/A
Karkus Ted William
2 Feb 23
4
Ted William Karkus
17 Jan 23
SC 13D/A
Karkus Ted William
17 Jan 23
3
Robert A. Jr. Morse
13 Jan 23
SC 13G
Lantern Pharma Inc.
21 Nov 22
SC 13D/A
Karkus Ted William
18 Oct 22
4
Ted William Karkus
18 Oct 22
SC 13D/A
Karkus Ted William
11 Aug 22
4
Ted William Karkus
10 Aug 22